
Invesco Pharmaceuticals ETF
PJPDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 26, 2026 | $0.27 | 2026-06-22 | 2026-06-22 |
| March 27, 2026 | $0.31 | 2026-03-23 | 2026-03-23 |
| December 26, 2025 | $0.25 | 2025-12-22 | 2025-12-22 |
| September 26, 2025 | $0.24 | 2025-09-22 | 2025-09-22 |
| June 27, 2025 | $0.27 | 2025-06-23 | 2025-06-23 |
Dividends Summary
- Consistent Payer: Invesco Pharmaceuticals ETF has rewarded shareholders with 75 dividend payments over the past 19 years.
- Total Returned Value: Investors who held PJP shares during this period received a total of $14.59 per share in dividend income.
- Latest Payout: The most recent dividend of $0.27/share was paid 22 days ago, on June 26, 2026.
- Yield & Schedule: PJP currently pays dividends quarterly with an annual yield of 0.89%.
- Dividend Growth: Since 2007, the dividend payout has grown by 1630.0%, from $0.02 to $0.27.
Company News
The article compares two healthcare-focused ETFs: Invesco Pharmaceuticals ETF (PJP) and First Trust NYSE Arca Biotechnology Index Fund (FBT). PJP focuses on established pharmaceutical companies with lower volatility and dividend income, while FBT targets high-growth biotech stocks with greater exposure to small and mid-cap companies. Despite FBT'...
VanEck Pharmaceutical ETF (PPH) offers a lower expense ratio (0.36%) and higher dividend yield (2.00%), making it ideal for income-focused investors, while Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (49.90% vs 27.10%) but has higher fees (0.57%). PPH provides global exposure with better 5-year performance, while PJP focus...
Pfizer announced that its Braftovi regimen demonstrated statistically significant improvements in progression-free survival and objective response rates for metastatic colorectal cancer patients with BRAF V600E mutation in the Phase 3 BREAKWATER trial, outperforming standard chemotherapy treatments. The stock is trading near 52-week highs with mi...
Smart Beta ETF report for PJP



